{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:14:48Z","timestamp":1790986488774,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2010,5,13]],"date-time":"2010-05-13T00:00:00Z","timestamp":1273708800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1007\/s10072-010-0262-0","type":"journal-article","created":{"date-parts":[[2010,5,12]],"date-time":"2010-05-12T16:52:32Z","timestamp":1273683152000},"page":"565-569","source":"Crossref","is-referenced-by-count":15,"title":["Effect of entacapone on plasma homocysteine levels in Parkinson\u2019s disease patients"],"prefix":"10.1007","volume":"31","author":[{"given":"Martin","family":"Nevrly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Kanovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Vranova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Langova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Hlustik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,5,13]]},"reference":[{"key":"262_CR1","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(03)00438-1","volume":"2","author":"MS Morris","year":"2003","unstructured":"Morris MS (2003) Homocysteine and Alzheimer\u2019s disease. Lancet Neurol 2:425\u2013428","journal-title":"Lancet Neurol"},{"key":"262_CR2","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1093\/jn\/130.12.3073","volume":"130","author":"MS Morris","year":"2000","unstructured":"Morris MS, Jacques PF, Rosenberg IH et al (2000) Serum total homocysteine concentration is related to self-reported heart attack or stroke history among men and women in the NHANES III. J Nutr 130:3073\u20133076","journal-title":"J Nutr"},{"key":"262_CR3","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/S0140-6736(95)92407-8","volume":"346","author":"IJ Perry","year":"1995","unstructured":"Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG (1995) Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 346:1395\u20131398","journal-title":"Lancet"},{"key":"262_CR4","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1056\/NEJM199804093381507","volume":"338","author":"GN Welch","year":"1998","unstructured":"Welch GN, Loscalzo J (1998) Homocysteine and atherothrombosis. N Engl J Med 338:1042\u20131050","journal-title":"N Engl J Med"},{"key":"262_CR5","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1056\/NEJMoa011613","volume":"346","author":"S Seshadri","year":"2002","unstructured":"Seshadri S, Beiser A, Selhub J et al (2002) Plasma homocysteine as a risk factor for dementia and Alzheimer\u2019s disease. N Engl J Med 346:476\u2013483","journal-title":"N Engl J Med"},{"key":"262_CR6","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00401-003-0676-3","volume":"105","author":"KA Jellinger","year":"2003","unstructured":"Jellinger KA (2003) Prevalence of cerebrovascular lesions in Parkinson\u2019s disease. A postmortem study. Acta Neuropathol (Berl) 105:415\u2013419","journal-title":"Acta Neuropathol (Berl)"},{"issue":"\/97","key":"262_CR7","first-page":"75","volume":"64","author":"D Kubov\u00e1","year":"2001","unstructured":"Kubov\u00e1 D, Rektor I (2001) Vaskul\u00e1rn\u00ed parkinsonsk\u00fd syndrom\u2014historie a sou\u010dasnost. \u010ces a Slov Neurol Neurochir 64(\/97):75\u201381","journal-title":"\u010ces a Slov Neurol Neurochir"},{"key":"262_CR8","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1212\/01.WNL.0000036610.36834.E0","volume":"59","author":"G Levy","year":"2002","unstructured":"Levy G, Tang MX, Louis ED et al (2002) The association of incident dementia with mortality in PD. Neurology 59:1708\u20131713","journal-title":"Neurology"},{"issue":"\/100","key":"262_CR9","first-page":"359","volume":"67","author":"I Rektorov\u00e1","year":"2004","unstructured":"Rektorov\u00e1 I (2004) \u00da\u010dinek donepezilu na demenci u Parkinsonovy nemoci a Alzheimerovy nemoci. Pilotn\u00ed studie. \u010ces a Slov Neurol Neurochir 67(\/100):359\u2013363","journal-title":"\u010ces a Slov Neurol Neurochir"},{"issue":"3","key":"262_CR10","first-page":"183","volume":"69\/102","author":"P Valkovi\u010d","year":"2006","unstructured":"Valkovi\u010d P, Bla\u017e\u00ed\u010dek P, Benetin J, Kukumberg P (2006) Homocyste\u00edn, levodopa a Parkinsonova choroba. \u010ces a Slov Neurol Neurochir 69\/102(3):183\u2013188","journal-title":"\u010ces a Slov Neurol Neurochir"},{"key":"262_CR11","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/clinchem\/47.6.1102","volume":"47","author":"F Blandini","year":"2001","unstructured":"Blandini F, Fancellu R, Martignoni E et al (2001) Plasma homocysteine and l-dopa metabolism in patients with Parkinson disease. Clin Chem 47:1102\u20131104","journal-title":"Clin Chem"},{"key":"262_CR12","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1212\/01.WNL.0000055899.24594.8E","volume":"60","author":"JW Miller","year":"2003","unstructured":"Miller JW, Selhub J, Nadeau MR, Thomas CA, Feldman RG, Wolf PA (2003) Effect of l-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology 60:1125\u20131129","journal-title":"Neurology"},{"key":"262_CR13","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0140-6736(99)01660-8","volume":"354","author":"T M\u00fcller","year":"1999","unstructured":"M\u00fcller T, Werne B, Fowler B, Kuhn W (1999) Nigral endothelial dysfunction, homocysteine, and Parkinson\u2019s disease. Lancet 354:126\u2013127","journal-title":"Lancet"},{"issue":"8","key":"262_CR14","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1179\/016164106X110445","volume":"28","author":"F Ozer","year":"2006","unstructured":"Ozer F, Meral H, Hanoglu L et al (2006) Plasma homocysteine levels in patients treated with levodopa: motor and cognitive associations. Neurol Res 28(8):853\u2013858","journal-title":"Neurol Res"},{"key":"262_CR15","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/archneur.60.1.59","volume":"60","author":"JD Rogers","year":"2003","unstructured":"Rogers JD, Sanchez-Saffon A, Frol AB, Diaz-Arrastia R (2003) Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. Arch Neurol 60:59\u201364","journal-title":"Arch Neurol"},{"key":"262_CR16","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.parkreldis.2005.01.007","volume":"11","author":"P Valkovi\u010d","year":"2005","unstructured":"Valkovi\u010d P, Benetin J, Bla\u017e\u00ed\u010dek P, Valkovi\u010dov\u00e1 \u013d, Gmitterov\u00e1 K, Kukumberg P (2005) Reduced plasma homocysteine levels in levodopa\/entacapone treated Parkinson patients. Parkinsonism Relat Disord 11:253\u2013256","journal-title":"Parkinsonism Relat Disord"},{"key":"262_CR17","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1034\/j.1600-0404.2003.00135.x","volume":"108","author":"K Yasui","year":"2003","unstructured":"Yasui K, Nakaso K, Kowa H, Takeshima T, Nakashima K (2003) Levodopa-induced hyperhomocysteinaemia in Parkinson\u2019s disease. Acta Neurol Scand 108:66\u201367","journal-title":"Acta Neurol Scand"},{"key":"262_CR18","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.parkreldis.2004.07.008","volume":"11","author":"S Zoccolella","year":"2005","unstructured":"Zoccolella S, Lamberti P, Armenise E et al (2005) Plasma homocysteine levels in Parkinson\u2019s disease: role of antiparkinsonian medications. Parkinsonism Relat Disord 11:131\u2013133","journal-title":"Parkinsonism Relat Disord"},{"issue":"8","key":"262_CR19","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1212\/01.WNL.0000158674.91134.6E","volume":"64","author":"JL Ostrem","year":"2005","unstructured":"Ostrem JL, Kang GA, Subramanian I et al (2005) The effect of entacapone on homocysteine levels in Parkinson disease. Neurology 64(8):1482","journal-title":"Neurology"},{"issue":"Suppl 2","key":"262_CR20","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1007\/PL00014300","volume":"157","author":"JD Finkelstein","year":"1998","unstructured":"Finkelstein JD (1998) The metabolism of homocysteine: pathways and regulation. Eur J Pediatr 157(Suppl 2):S40\u2013S44","journal-title":"Eur J Pediatr"},{"key":"262_CR21","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1146\/annurev.nutr.19.1.217","volume":"19","author":"J Selhub","year":"1999","unstructured":"Selhub J (1999) Homocysteine metabolism. Annu Rev Nutr 19:217\u2013246","journal-title":"Annu Rev Nutr"},{"key":"262_CR22","first-page":"1541","volume":"63","author":"American Society of Human Genetics\/American College of Medical Genetics Test, Transfer Committee Working Group","year":"2008","unstructured":"American Society of Human Genetics\/American College of Medical Genetics Test, Transfer Committee Working Group (2008) Measurement and use of total plasma homocysteine. Am J Hum Genet 63:1541\u20131543","journal-title":"Am J Hum Genet"},{"key":"262_CR23","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1161\/01.ATV.11.5.1129","volume":"11","author":"JJ Genest Jr","year":"1991","unstructured":"Genest JJ Jr, McNamara JR, Upson B et al (1991) Prevalence of familial hyperhomocyst(e)inemia in men with premature coronary artery disease. Arterioscler Thromb 11:1129\u20131136","journal-title":"Arterioscler Thromb"},{"key":"262_CR24","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1023\/A:1022130217463","volume":"16","author":"WG Haynes","year":"2002","unstructured":"Haynes WG (2002) Hyperhomocysteinemia, vascular function and atherosclerosis: effects of vitamins. Cardiovasc Drugs Ther 16:391\u2013399","journal-title":"Cardiovasc Drugs Ther"},{"key":"262_CR25","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1056\/NEJM199502023320502","volume":"332","author":"J Selhub","year":"1995","unstructured":"Selhub J, Jacques PF, Bostom AG et al (1995) Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 332:286\u2013291","journal-title":"N Engl J Med"},{"key":"262_CR26","first-page":"1392","volume":"41","author":"O Stanger","year":"2003","unstructured":"Stanger O, Herrmann W, Pietrzik K et al (2003) DACH-LIGA homocystein (german, austrian and swiss homocysteine society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations. Clin Chem Lab Med 41:1392\u20131403","journal-title":"Clin Chem Lab Med"},{"key":"262_CR27","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0166-2236(03)00032-8","volume":"26","author":"MP Mattson","year":"2003","unstructured":"Mattson MP, Shea TB (2003) Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci 26:137\u2013146","journal-title":"Trends Neurosci"},{"key":"262_CR28","first-page":"527","volume":"16","author":"P Allain","year":"1995","unstructured":"Allain P, Le BA, Cordillet E, Le QL, Bagheri H, Montastruc JL (1995) Sulfate and cysteine levels in the plasma of patients with Parkinson\u2019s disease. Neurotoxicology 16:527\u2013529","journal-title":"Neurotoxicology"},{"key":"262_CR29","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000007984","volume":"40","author":"W Kuhn","year":"1998","unstructured":"Kuhn W, Roebroek R, Blom H et al (1998) Elevated plasma levels of homocysteine in Parkinson\u2019s disease. Eur Neurol 40:225\u2013227","journal-title":"Eur Neurol"},{"key":"262_CR30","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1301\/002966402320964089","volume":"60","author":"JW Miller","year":"2002","unstructured":"Miller JW (2002) Homocysteine, folate deficiency, and Parkinson\u2019s disease. Nutr Rev 60:410\u2013413","journal-title":"Nutr Rev"},{"key":"262_CR31","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0022-510X(02)00353-2","volume":"207","author":"K Nakaso","year":"2003","unstructured":"Nakaso K, Yasui K, Kowa H et al (2003) Hypertrophy of IMC of carotid artery in Parkinson\u2019s disease is associated with l-DOPA, homocysteine, and MTHFR genotype. J Neurol Sci 207:19\u201323","journal-title":"J Neurol Sci"},{"key":"262_CR32","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/mds.20253","volume":"19","author":"PE O\u2019Suilleabhain","year":"2004","unstructured":"O\u2019Suilleabhain PE, Bottiglieri T, Dewey RB Jr, Sharma S, Diaz-Arrastia R (2004) Modest increase in plasma homocysteine follows levodopa initiation in Parkinson\u2019s disease. Mov Disord 19:1403\u20131408","journal-title":"Mov Disord"},{"key":"262_CR33","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1212\/WNL.55.3.437","volume":"55","author":"K Yasui","year":"2000","unstructured":"Yasui K, Kowa H, Nakaso K, Takeshima T, Nakashima K (2000) Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology 55:437\u2013440","journal-title":"Neurology"},{"key":"262_CR34","first-page":"165","volume":"39","author":"SE Daniel","year":"1993","unstructured":"Daniel SE, Lees AJ (1993) Disease Society Brain Bank, London: overview and research. J Neural Transm Suppl 39:165\u2013172","journal-title":"J Neural Transm Suppl"},{"issue":"1","key":"262_CR35","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1373\/clinchem.2003.021634","volume":"50","author":"H Refsum","year":"2004","unstructured":"Refsum H, Smith AD, Ueland PM et al (2004) Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem 50(1):3\u201332","journal-title":"Clin Chem"},{"key":"262_CR36","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1468-1331.2004.00973.x","volume":"12","author":"P Lamberti","year":"2005","unstructured":"Lamberti P, Zoccolella S, Armenise E et al (2005) Hyperhomocysteinemia in l-dopa treated Parkinson\u2019s disease patients: effect of cobalamin and folate administration. Eur J Neurol 12:365\u2013368","journal-title":"Eur J Neurol"},{"issue":"\/98","key":"262_CR37","first-page":"69","volume":"65","author":"M Bare\u0161","year":"2002","unstructured":"Bare\u0161 M, Ka\u0148ovsk\u00fd P, Rektor I (2002) \u00daloha inhibitor\u016f katechol-O-metyl-transfer\u00e1zy (COMT) v l\u00e9\u010db\u011b pozdn\u00edch komplikac\u00ed Parkinsonovy nemoci\u2014\u00fa\u010dinnost a\u00a0bezpe\u010dnost entakaponu (Comtan\u00ae). \u010ces a Slov Neurol Neurochir 65(\/98):69\u201375","journal-title":"\u010ces a Slov Neurol Neurochir"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-010-0262-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10072-010-0262-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-010-0262-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T15:01:40Z","timestamp":1591282900000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10072-010-0262-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,13]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["262"],"URL":"https:\/\/doi.org\/10.1007\/s10072-010-0262-0","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,13]]}}}